Search

Displaying results 7811 - 7820 of 10000 in total
  1. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

  3. Drug

    TC-2216

    go.drugbank.com/drugs/DB06044
    Investigational

    TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. … TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reuptake inhibitors and tricyclics, which are commonly used treatments for depression, as well as anxiety-relieving

    Synonyms: 1,7-DIAZASPIRO(4.4)NONANE, 7-(3-PYRIDINYL)-, HYDROCHLORIDE (1:3)
  4. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.

    Products: CABLIVI®, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET
  6. Drug

    ICA-105665

    go.drugbank.com/drugs/DB06089
    Investigational

    ICA-105665 is a novel small molecule compound for the treatment of epilepsy. … It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy.

  7. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). … It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.

  8. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). … The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases.

  9. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia. … AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do

  10. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector